opment than total fat mass in obese individuals. [9] [10] [11] However, prior work has been limited by small sample sizes, homogeneous patient populations, and absence of longitudinal follow-up for diabetes incidence. Furthermore, data are lacking regarding discrimination of prediabetes or diabetes risk specifically in obese adults. Therefore, we investigated associations of baseline adipose tissue distribution, adipokines, lipids, and biomarkers of insulin resistance and inflammation with the risk of incident prediabetes and diabetes in a multiethnic cohort of obese adults with extensive cardiovascular, metabolic, and adipose tissue phenotyping.
METHODS
The Dallas Heart Study (DHS) is a multiethnic, probability-based, population cohort study of Dallas County adults, with deliberate oversampling of African American individuals. Detailed methods of DHS phase 1 (DHS-1) have been described previously. 12 Between 2000 and 2002, 3072 participants completed DHS-1, including a detailed survey, laboratory testing, and multiple imaging studies. Among participants completing DHS-1 who were obese at enrollment (n = 1425), those with preexisting diabetes or clinical CVD (coronary heart disease [CHD], heart failure, or ischemic stroke) were excluded (n = 348), resulting in 1077 participants eligible for follow-up.
In DHS phase 2 (DHS-2), participants who completed DHS-1 underwent a follow-up survey, laboratory testing, and repeat imaging studies during a single visit to the University of Texas (UT) Southwestern Medical Center between September 2007 and December 2009. Among 1077 participants eligible for follow-up, 345 did not complete DHS-2, resulting in a final sample size of 732. There were no major differences in medical history, demographics, or biomarker data between eligible participants who did and did not complete DHS-2 (eTable 1, available at http://www.jama.com). Within this cohort, we also examined a subgroup with normal fasting blood glucose (FBG) values at baseline (n=512). All participants provided written informed consent, and the protocol was approved by the UT Southwestern institutional review board.
Type 2 Diabetes and Prediabetes Ascertainment
At baseline, diabetes was defined by prevalent medical treatment for diabetes, an FBG of 126 mg/dL or greater, or a nonfasting BG level 200 mg/dL or greater (to convert glucose to mmol/L, multiply by 0.0555). At follow-up, incident diabetes was defined by initiation of medical treatment for diabetes during the study interval, an FBG of 126 mg/dL or greater, a nonfasting BG of 200 mg/dL or greater, or glycated hemoglobin (HbA 1c ) 6 .5% or greater, according to updated guidelines 13 (HbA 1c was not measured in DHS-1). No information was available regarding the time of diagnosis or onset of incident diabetes. Family history of diabetes was defined as any first-degree relative with diabetes.
At baseline, prediabetes was defined by the 2003 American Diabetes Association criteria for impaired fasting glucose (IFG) as an FBG of 100 to 125 mg/dL.
14 At follow-up, incident prediabetes was defined as either new IFG with an FBG of 100 to 125 mg/dL or HbA 1c of 5.7% to 6.4%. 13 Oral glucose tolerance testing was not performed.
Variable Definitions
Obesity was defined as a BMI of 30 or greater, calculated as weight in kilograms divided by height in meters squared. Race/ethnicity, history of CVD, medication usage, and smoking status were self-reported. Definitions for hypertension, hypercholesterolemia, and low high-density lipoprotein (HDL) cholesterol have been previously described using conventional clinical definitions. 15 Metabolic syndrome was defined and Framingham 10-year CHD risk estimates were calculated according to the National Cholesterol Education Program Adult Treatment Panel III report. 16 The homeostasis model assessment of insulin resistance index (HOMA-IR) was calculated with the following: (fasting insulin [µIU/ mL] ϫ fasting glucose [mmol/L]) divided by 22.5. 17 Physical activity was derived using self-reported frequency and type of leisure-time physical activity and a standard conversion for metabolic equivalence units (METs).
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Body Composition Measurements
Body surface area (BSA) was calculated using the method of Tikuisis et al. 19 Waist circumference was measured 1 cm above the iliac crest and hip circumference at the widest circumference of the buttocks at the area of the greater trochanters. Dual-energy x-ray absorptiometry (Delphi W scanner, Hologic, and Discovery software version 12.2) was used to measure total body fat, lean mass, truncal fat, and lower body fat. Lower body fat was delineated by 2 oblique lines crossing the femoral necks and converging below the pubic symphysis and included glutealfemoral fat. 20 Visceral and subcutaneous abdominal fat mass were measured by 1.5-T MRI (Intera, Philips Medical Systems) using a prospectively designed and validated method of fat mass prediction from a single MRI slice at the L2-L3 intervertebral level. 21 Single-slice measurement of subcutaneous and visceral fat mass at this intervertebral level has been shown to be highly concordant with total abdominal fat mass measured at all intervertebral levels (R 2 = 85%-96%). 21 Liver fat was measured using 1.5-T proton magnetic resonance spectroscopy and is reported as a percentage of signal from fat to total signal from fat and water. 22 
Biomarker Measurements
Biomarkers reported in this study have been measured previously and the analytical methods described for levels of leptin, 23 adiponectin, 24 high-sensitivity C-reactive protein (hsCRP), 25 and fructosamine. 26 Particle concentrations of low-density lipoprotein (LDL), HDL, and very low-density lipoprotein (VLDL) subclasses were measured by LipoScience using nuclear magnetic resonance spectroscopy. 27 In DHS-2, standard laboratory assays were used to measure cholesterol and glucose, and HbA 1c was measured using an Ultra-2 affinity high-performance liquid chromatography assay (Trinity Biotech). The interassay coefficients of variation were 2.9%, 1.8%, and 1.1% at HbA 1c levels of 5.1%, 8.6%, and 19.5%, respectively.
Cardiac and Vascular Imaging Measurements
Electron-beam computed tomography measurements of coronary artery calcium (CAC) were performed in duplicate on an Imatron 150 XP scanner, and the scores were averaged. Prevalent CAC was defined as a mean Agatston score greater than 10. 28 Cardiac and aortic MRI were performed using 1.5-T MRI, and left ventricular mass and wall thickness, aortic compliance, and aortic plaque area and wall thickness were calculated according to previously published methods.
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Statistical Analysis
Characteristics were compared between participants with and without diabetes at follow-up using 2 tests for dichotomous variables and Wilcoxon rank-sum tests for continuous variables. In the subgroup with normal FBG levels at baseline, comparisons among participants who remained free of prediabetes or diabetes, developed prediabetes, and developed diabetes were made using the Jonckheere-Terpstra trend test. Comparisons of diabetes incidence across sex-specific tertiles of visceral, abdominal subcutaneous, and total body fat mass were performed with the Jonckheere-Terpstra trend test; for the subgroup with normal FBG levels, a composite end point of prediabetes or diabetes was used. Analyses of incident diabetes stratified by median visceral fat mass and by HOMA-IR and fructosamine levels were also performed. Among participants with normal baseline FBG levels, stratified analyses were performed assessing unadjusted associations between visceral fat mass and the composite of incident prediabetes or diabetes across subgroups defined by sex, race, BMI, metabolic syndrome, and weight gain.
Multivariable logistic regression modeling using a backward selection strategy was performed to identify idependent associations of baseline variables with incident diabetes. Candidate variables were selected for inclusion based on a P value less than .10 in unadjusted analyses, and those with an adjusted P value less than .05 were retained in the final model. In the subgroup with normal FBG levels at baseline, similar modeling was performed using the composite of prediabetes or diabetes as the outcome variable because of the small numbers of diabetes events in the subgroup. In addition to baseline variables, weight gain between study visits was tested in both models. Visceral fat mass, FBG level, fructosamine level, insulin level, and HOMA-IR were log-transformed and modeled per 1-SD increment of the log-transformed variable; these SD increments were also backtransformed to provide more clinically relevant increments. For variables providing similar information (eg, VLDL particles and triglyceride levels), only the most clinically relevant measurement was tested. Cardiovascular and atherosclerosis imaging variables were not tested in the models. Adjusted absolute risk changes associated with each independent variable were estimated assuming mean levels of other covariates in the models.
For all statistical testing, a 2-sided P value less than .05 was considered statistically significant without correction for multiple comparisons. All statistical analyses were performed using SAS version 9.2 (SAS Institute).
RESULTS
Incident Diabetes
The study cohort included 732 obese participants followed up for a median period of 7 years (interquartile range [IQR], 6.6-7.6), resulting in 5207 person-years of follow-up (FIGURE 1). Incident diabetes developed in 84 participants (11.5%), among whom 45 (53.6%) had IFG at baseline; 12 participants were diagnosed exclusively by HbA 1c criteria. At baseline, participants who subsequently developed diabetes were more likely than those who remained free of diabetes to have IFG, family history of diabetes, hypertension, and the metabolic syndrome with higher HOMA-IR, higher levels of fructosamine and triglycerides, and a higher concentration of large VLDL particles. Lower body fat mass, adiponectin levels, and large HDL and LDL particle concentrations were inversely associated with incident diabetes (TABLE 1 and TABLE 2) . Follow-up characteristics of those with and without incident diabetes are shown in TABLE 3.
Diabetes incidence increased significantly across sex-specific tertiles of visceral fat mass (PϽ .001 for trend), but no association was seen for abdominal subcutaneous fat or total body fat (TABLE 4). Stratification by markers of insulin resistance demonstrated additive associations of visceral fat mass with both HOMA-IR (FIGURE 2A) and fructosamine level ( Figure 2B ) for incident diabetes. Baseline waist circumference, waist-to-hip ratio, and liver fat percentage were also associated with incident diabetes, but markers of general adiposity including BMI, truncal fat mass, and hsCRP level were not (Table 1 and Table 2 ).
Compared with individuals who did not develop diabetes, those with incident diabetes had higher baseline Framingham 10-year CHD risk estimates, increased aortic wall thickness and aortic plaque, and decreased aortic compliance. Left ventricular mass and wall thickness were also higher at baseline in participants who subsequently developed diabetes (PϽ.05 for each) ( Table 2) .
In 
Participants With Normal FBG Levels at Baseline
Among 512 individuals with normal FBG levels (Ͻ100 mg/dL) at baseline, 161 (31.4%) subsequently developed prediabetes and 39 (7.6%) progressed to diabetes ( Figure 1) ; 67 participants were diagnosed with prediabetes exclusively by HbA 1c measurement. Within this subgroup, graded associations were observed with visceral fat mass, waist circumference, waist-tohip ratio, and liver fat percentage between participants who remained normoglycemic, those who developed prediabetes, and those who progressed to diabetes (P Ͻ0.01 for trend for each) (eTable 2). Lower body fat mass and adiponectin level showed graded, inverse associations with incident prediabetes and diabetes (P Յ.01 for trend for each) (eTable 2). In contrast, general adiposity markers including BMI, abdominal subcutaneous fat mass, and hsCRP level were not associated with incident prediabetes or diabetes (eTable 2). The median change in body weight for participants who did not develop prediabetes or diabetes was 1.6 kg (IQR, −4.1 to 7.7) vs 4.5 kg (IQR, −0.5 to 10.5) for those who developed prediabetes and 7.2 kg (IQR, 3.5 to 17.4) for those who progressed to diabetes (P Ͻ.001 for trend) (eTable 2).
When participants were divided into sex-specific tertiles of visceral fat, subcutaneous abdominal fat, and total body fat, a graded association across tertiles of visceral fat was observed for the composite of prediabetes or diabetes (P=.02 for trend), but no association was seen across tertiles of subcutaneous or total body fat (Table 4 ). Visceral fat mass demonstrated similar associations with the composite of incident prediabetes or diabetes across subgroups defined by sex, race, obesity class, presence of metabolic syndrome, and weight gain, with no interactions detected (eFigure).
In Abbreviations: BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; METs, metabolic equivalence units; VLDL, very low-density lipoprotein. SI conversion factors: To convert glucose to mmol/L, multiply by 0.0555; HDL-C, LDL-C, and VLDL to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113. a Calculated as weight in kilograms divided by height in meters squared. b n=565 and n=74 for the no diabetes and incident diabetes groups, respectively. c Concentration of large particles.
adiposity that are associated with diabetes in the general population, such as BMI, total body fat, and abdominal subcutaneous fat, were not associated with prediabetes or diabetes incidence in this obese population. These findings suggest that clinically measurable markers of adipose tissue distribution and insulin resistance may be useful in prediabetes and diabetes risk discrimination among obese individuals and support the notion of obesity as a heterogeneous disorder with distinct adiposity subphenotypes.
Adiposity Phenotypes and the Transition to Diabetes
Prior cross-sectional studies have reported a strong correlation between visceral fat and insulin resistance in obese white 11 and African American populations. 33 However, studies of incident Abbreviations: BSA, body surface area; CHD, coronary heart disease; DEXA, dual-energy x-ray absorptiometry; LV, left ventricular; METs, metabolic equivalence units; MRI, magnetic resonance imaging. a n=565 and n=74 for the no diabetes and incident diabetes groups, respectively. b n=519 and n=65 for the no diabetes and incident diabetes groups, respectively. 32 (mean BMI, 27) that hypertension, hyperglycemia, and family history of diabetes were independently associated with incident diabetes. Additionally, we found that visceral adiposity, increased liver fat, decreased lower body fat, insulin resistance, elevated triglycerides, and low adiponectin levels were associated with incident prediabetes and diabetes in obese individuals while markers of general adiposity were not.
To our knowledge, only a single prospective study (performed in non- Abdominal subcutaneous fat, mean (range), kg obese Japanese American individuals) has examined the association of abdominal fat distribution with incident diabetes. 10 In that study, visceral adipose tissue area, characterized by computed tomography, was independently associated with diabetes while markers of general adiposity demonstrated weaker and inconsistent associations. Our results confirm that visceral, but not general, adiposity was independently associated with incident diabetes in a diverse population of obese individuals with a high proportion of women and African American participants while extending this knowledge to both incident prediabetes and diabetes. Importantly, although women and African American individuals have less visceral fat than men and white individuals, respectively, 35 we observed similar associations of visceral fat with prediabetes and diabetes incidence across subgroups defined by sex and race.
Fasting glucose is known to be an insensitive measure of insulin resistance in obese persons. 13 Notably, we found that even among obese individuals with normal FBG levels at enrollment, those who subsequently developed prediabetes or diabetes had baseline evidence of insulin resistance (higher HOMA-IR) and impaired intermediateterm glycemic control (higher fructosamine level), with moderate elevations in HOMA-IR and fructosamine among those who developed prediabetes and more marked elevations in those who developed diabetes. These findings suggest that prediabetes may represent a true intermediate phenotype between metabolically healthy obesity and diabetes.
The mechanisms behind the transition from functional to dysfunctional adiposity are not well understood. Subcutaneous adipose tissue acts as a functional site of fat storage; accumulation of fat leads to hyperplastic expansion of the subcutaneous compartment and ensuing obesity. However, the amount of subcutaneous fat might not differ between insulin-sensitive and insulinresistant individuals. 36 In fact, subcutaneous fat mass transplantation into rodents has beneficial metabolic effects, suggesting that the expandability of subcutaneous fat may be a critical factor in maintaining healthy obesity. 37 A deficient expansion of the subcutaneous fat depot may promote ectopic fat deposition with excessive free fatty acid and adipokine release leading to lipotoxicity and insulin resistance in muscle, liver, and pancreatic ␤ cells. This may be especially apparent in obese persons in whom functional fat storage is overwhelmed by excess energy input. In these individuals, ectopic fat deposition in the viscera and liver may indicate deficient fat storage capacity in subcutaneous adipose tissue.
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Understanding Metabolically Healthy Obesity
Our study may have implications for understanding differences between metabolically healthy and pathologic obesity. 39 The current findings suggest that a more metabolically healthy obesity phenotype is associated with decreased fat deposition in the abdominal viscera, increased lower body subcutaneous fat storage, insulin sensitivity, increased adiponectin, and a favorable lipoprotein profile characterized by larger HDL and LDL particles. Importantly, we observed that BMI, total body fat, and abdominal subcutaneous fat mass did not differ between the 2 groups, suggesting that resistance to diabetes in these individuals may be explained by the ability to shunt excess fat away from visceral and other ectopic sites and preferentially deposit it in the lower body subcutaneous compartment. Indeed, participants who remained free from prediabetes and diabetes in our study had more lower body subcutaneous fat than those who developed metabolic disease. This key finding supports prior cross-sectional data 20 suggesting that lower body subcutaneous fat may protect against adiposity-associated metabolic disease. However, the biological factors that determine whether an individual obese person will favor visceral vs expandable subcutaneous storage are unknown and remain an essential area for further research.
Adiposity Phenotypes and Cardiovascular Risk
Although participants with clinically evident CVD were excluded from our study, we observed a more adverse cardiovascular risk profile and evidence of greater subclinical CVD at baseline among obese individuals who subsequently developed prediabetes or diabetes. Participants who developed prediabetes or diabetes had only slightly higher 10-year estimated CHD risk at baseline, yet we observed a higher baseline prevalence of CAC, aortic plaque, and left ventricular hypertrophy and greater aortic wall thickness and lower aortic compliance among those who subsequently developed metabolic disease. These findings raise the possibility that in addition to effects on metabolic parameters, visceral fat deposition and insulin resistance may contribute directly, indirectly, or both to subclinical CVD and adverse cardiac and vascular remodeling prior to the clinical manifestations of metabolic disease.
Strengths and Limitations
Strengths of the current study include a diverse sample of adults applicable to the general obese population, extensive and detailed phenotyping using advanced imaging and laboratory techniques, and longitudinal follow-up in a prospective cohort. Limitations include the absence of glucose tolerance testing in the DHS and lack of HbA 1c measurements in DHS-1. In addition, the number of diabetes events was modest and information was not available with regard to time of prediabetes or diabetes onset. Findings are not necessarily generalizable to individuals older than 65 years or those of Asian descent/ethnicity.
Clinical Implications
In a multiethnic, population-based sample of obese adults, a dysfunctional adiposity phenotype, characterized by excess visceral fat and insulin resistance, identified obese individuals at risk for prediabetes and diabetes, whereas markers of general adiposity did not. Identification of high-risk obese individuals in the clinical setting is an important but elusive goal. Because the metabolic consequences of obesity are not predictable based on simple anthropometric measurements, 40 new tools are needed to identify appropriate candidates for intensive lifestyle modification and therapeutic interventions. In addition, therapies for obesity such as bariatric surgery or pharmacologic treatment may be tailored to individuals at greatest risk of developing diabetes.
The inclusion of adipose distribution assessment in our multivariable model yielded robust discrimination of diabetes incidence (C statistic, 0.85), outperforming a clinical model developed previously in a white, nonobese population. 32 Further research is needed to determine whether assessment of adipose tissue distribution and function using imaging tools, circulating biomarkers, or both can improve clinical risk prediction in obese individuals. Moreover, the present findings also suggest that the development of novel therapies that modify adipose tissue distribution may improve metabolic and cardiovascular outcomes in obese individuals. The association between weight gain and incident prediabetes and diabetes in our cohort suggests that preventing weight gain, even among those already obese, may favorably affect metabolic health independent of baseline adipose tissue distribution.
